Context Therapeutics (CNTX) Other financing activities (2021 - 2025)
Context Therapeutics' (CNTX) quarterly Other financing activities came in at $15268.0 in Q1 2025, down 85.04% quarter-over-quarter from $102071.0 in Q1 2022.
Context Therapeutics (CNTX) Other financing activities (2021 - 2025) Analysis & Trends
Context Therapeutics has disclosed Other financing activities across 3 years of filings, most recently posting $15268.0 for Q1 2025.
- Other financing activities for Q1 2025 came in at $15268.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $15268.0 (changed N/A YoY), and the FY2025 annual result was $15268.0, changed N/A from the prior year.
- Other financing activities came in at $15268.0 for Q1 2025 at Context Therapeutics, down from $102071.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $816917.0 in Q3 2021 to a low of -$716917.0 in Q4 2021.
- The 3-year median for Other financing activities is $58669.5 (2022), against an average of $54334.8.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 15,268.00 |
| Mar 31, 2025 | 15,268.00 |
| Mar 31, 2022 | 102,071.00 |
| Mar 31, 2022 | 102,071.00 |
| Dec 31, 2021 | -716,917.00 |
| Dec 31, 2021 | -716,917.00 |
| Sep 30, 2021 | 816,917.00 |
| Sep 30, 2021 | 816,917.00 |